ERBB2 and invasive breast carcinoma: A core needle biopsy revealed an invasive breast carcinoma of no special type (NST), grade 3, with Ki67 35%, stromal tumor-infiltrating lymphocytes (sTILs) 15%, ER expression >90%, PgR expression >90%, HER2 IHC score 2+, with ERBB2 gene amplified according to a fluorescent in situ hybridization (FISH) for a HER2/CEP17 ratio of 2.1 and mean HER2/cell signal of 7.4 [3].